Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price dropped 4.4% on Friday . The company traded as low as $38.50 and last traded at $38.95. Approximately 1,112 shares changed hands during trading, a decline of 98% from the average daily volume of 48,576 shares. The stock had previously closed at $40.74.
Analysts Set New Price Targets
Separately, JPMorgan Chase & Co. initiated coverage on Ascentage Pharma Group International in a research report on Thursday, March 27th. They set an "overweight" rating on the stock.
Check Out Our Latest Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Down 6.1%
The stock's fifty day simple moving average is $31.22. The company has a debt-to-equity ratio of 3.24, a current ratio of 1.26 and a quick ratio of 1.26.
Hedge Funds Weigh In On Ascentage Pharma Group International
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new stake in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned about 0.18% of Ascentage Pharma Group International at the end of the most recent reporting period.
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Further Reading
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
